Traditional and Modified Algorithm-Based Designs for Phase I Cancer Clinical Trials

Statistical Methods for Dose-Finding Experiments

Volumn , Issue , 2006, Pages 59-90

  Shih, Weichung Joe ^a,b   Lin, Yong ^a,b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Attained target toxicity level (ATTL); Exact dose toxicity curve; M1 A + B design; Notation and convention; Phase I cancer clinical trials; Phase I cancer clinical trials and algorithm based designs; Traditional algorithm based designs; Traditional and modified algorithm based designs

Indexed keywords

TOXICITY;

ALGORITHM-BASED DESIGNS; ATTAINED TARGET TOXICITY LEVEL (ATTL); CLINICAL TRIAL; EXACT DOSE-TOXICITY CURVE; MODIFIED ALGORITHMS; NOTATION AND CONVENTION;

DISEASES;

EID: 40449104909     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470861258.ch3     Document Type: Chapter

References (11)

1. S.K. Carter (1987) The phase I study, in Fundamentals of Cancer Chemotherapy (eds K.K. Hellmann and S.K. Carter), McGraw-Hill, New York, pp. 285-300.
2. S.F. Dent and E.A. Eisenhauer (1996) Phase I trial design: are new methodologies being put into practice? Ann. Oncology, 7(6), 561-6.
3. L. Edler (1990) Statistical requirements of phase I studies. Onkologie, 13(2), 90-5.
4. J.M. Heyd and B. Carlin (1999) Adaptive design improvements in the continual reassessment method for phase I studies. Statistics in Medicine, 18(11), 1307-21.
5. J. O'Quigley, M. Pepe and L. Fisher (1990) Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics, 46(1), 33-48.
6. Y. Lin and W.J. Shih (2001) Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics, 2(2), 203-15.
7. Y. Lin andW.J. Shih (2004) Statistical properties of the modified algorithm-based designs for phase I cancer clinical trials. Technical report, Department of Biostatistics, University of Medicine and Dentistry of New Jersey.
8. T.L. Smith, J.J. Lee, H.M. Kantarjian, S.S. Legha and M.N. Raber (1996) Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J. Clin. Oncology, 14(1), 287-95.
9. E. Poplin, E. Rubin, B. Kamen and J. Bertino (2004) A phase I study of oral capecitabine, trimetrexate and leucovorin (TRI-X) in patients with metastatic or recurrent cancer. Technical report, Clinical trial protocol of the Cancer Institute of New Jersey.
10. D. Gibbon, E. Rubin and J. Aisner (2001) A Phase I trial for the combination IV paclitaxel and carboplatin with escalating doses of intraperitoneal gemcitabine in patients with epithelial ovarian cancer. Technical report, Clinical trial protocol of the Cancer Institute of New Jersey.
11. M. Wojtowicz, Y. Elsayed, D. Schaar and E. Rubin (2003) A phase I study of the novel kinase insert-domain-containing receptor (KDR) and fms-like tyrosine kinase-3 (flt-3) inhibitor, L-000021649 in patients with advanced hematologic and non-hematologic malignancies. Technical report, Clinical trial protocol of the Cancer Institute of New Jersey.